Kiang-Teck Jerry Yeo

Professor & Laboratory Director

University of Chicago

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kiang-Teck Jerry Yeo is a Professor and Laboratory Director at the University of Chicago, USA. His research primarily focuses on pharmacogenomics, patient outcomes, and risk assessment in clinical settings, as evidenced by his recent articles on pharmacogenetics tools, preeclampsia risk assessment, and the implementation of precision medicine. Additionally, he contributes to improving laboratory practices, such as reducing specimen rejection rates and addressing biotin interference in immunoassays.

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (5)

Edith Nutescu

Professor and Department Head

University of Illinois Chicago College of Pharmacy

UNITED STATES

View details

Natalie Reizine

Assistant Professor

University of Chicago

UNITED STATES

View details

Joana Lopes Perdigao

University of Chicago

UNITED STATES

View details

James Lee

University of Chicago

UNITED STATES

View details

Minoli Perera

Associate Professor

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kiang-Teck Jerry Yeo

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Impact of First‐of‐Its‐Kind Patient‐Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes

Impact of PlGF immunoassay imprecision on preeclampsia risk assessment with the sFlt-1 to PlGF ratio

Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive CYP2D6 Genotyping in Cancer Palliative Care

Implementation of pharmacogenomics testing for precision medicine

Is the automated Elecsys tacrolimus assay on the Roche cobas e 602 analyzer an acceptable replacement for a liquid chromatography–tandem mass spectrometry–based assay?

Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen

Reducing Specimen Rejection Rates Using Concentration-Dependent Hemolysis Rejection Thresholds

Biotin Interference in Immunoassays and Patient Safety

Use of a Vanadate Oxidation Conjugated Bilirubin Assay to Reduce Test Cancellations Resulting from Hemolyzed Specimens in Pediatric Patients

Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia

Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti–SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer

Triiodothyroacetic Acid Cross-Reacts With Measurement of Triiodothyronine (T3) on Various Immunoassay Platforms

Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients.

Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients

Collaborators (5)

Edith Nutescu

Natalie Reizine

Joana Lopes Perdigao

James Lee

Minoli Perera

Make your next move.